LearnGlossaryMarketStocksSuperinvestorsSign in

VRDN

Viridian Therapeutics, Inc.

Healthcare · $2.2B market cap

Verdict

We can't put a fair value on VRDN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-14.2% a year✗
Sales growth35.6% a year✓
Free cash flow growth—?
Return on invested capital-47.2%✗

Follow VRDN

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works